Gastrointestinal Stromal Tumor

“There are many exciting studies in progress to look forward to” at future Connective Tissue Oncology Society meetings, according to Candace Haddox, MD.

Candace Haddox, MD, explored advances in genetic sequencing for sarcomas, which was a major theme of the Connective Tissue Oncology Society Annual Meeting, in this video interview with Healio.

Healio spoke with Sandra D’Angelo, MD, about a study of rogaratinib in patients with succinate dehydrogenase-deficient gastrointestinal stromal tumor presented at the Connective Tissue Oncology Society Annual Meeting.

The FDA granted orphan drug designation to several therapies in development for oncology indications.

Rare Disease Day is Feb. 28.

Ripretinib did not extend PFS compared with sunitinib for patients with advanced gastrointestinal stromal tumor who previously received imatinib, according to randomized phase 3 study results presented during the ASCO Plenary Series.

Ripretinib failed to prolong PFS compared with sunitinib among patients with gastrointestinal stromal tumor who received prior treatment with imatinib, according to results of the phase 3 INTRIGUE study released by the agent’s manufacturer.

Tumor rupture appeared associated with shorter OS among patients treated with or without imatinib after surgery for gastrointestinal stromal tumors, or GIST, according to results of a post-hoc observational study published in JAMA Surgery.

An extended course of imatinib increased OS among patients with gastrointestinal stromal tumors, or GIST, according to long-term study results presented during the ASCO20 Virtual Scientific Program.

The FDA granted priority review to ripretinib for treatment of advanced gastrointestinal stromal tumors, according to a press release from the agent’s manufacturer.